期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 30, 期 23, 页码 -出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2020.127514
关键词
Structural hybridization; Antimalarial hybrids; Antibacterial hybrids; Anticancer hybrids; Antiviral hybrids
资金
- Deutsche Forschungsgemeinschaft (DFG) [TS 87/16-3]
- Alexander von Humboldt (AvH) foundation
- Interdisciplinary Center for Molecular Materials (ICMM)
- Graduate School Molecular Science (GSMS)
- Friedrich-Alexander-Universitat ErlangenNurnberg
Structural hybridization of preclinically and clinically validated pharmacologically active molecules has emerged as a promising tool to develop new generations of safe and highly efficient drug candidates against various diseases including microbial infections, virus infections and cancer. Strategies of drug-drug combinations have been adopted to generate hybrid conjugates of many clinically used drugs, designed to address inherent problems associated with these drugs. Thus, the design of hybrids was aimed to achieve higher efficacy through possible multi-target interactions, selective delivery of the drug to the site of action with the aim to improve bioavailability, alleviate toxicity and circumvent drug resistances. In this review article, we summarize the progress made in recent years in the rapidly growing field of drug discovery, focusing on the rationality of the hybrid design with particular emphasis on the linker architecture, which plays a crucial role in the overall success of a hybrid drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据